PolarityBio Receives U.S. FDA Breakthrough Therapy Designation for Treatment of Wagner Grade I Diabetic Foot Ulcers (DFU)
The FDA has granted Breakthrough Therapy Designation for SkinTE based on key positive data from the Phase II study in Wagner1 DFUs highlighting ...
EurekAlert!4d
Key risk factors for diabetic foot reinfections uncovered in UT Health San Antonio study
A study published in the International Wound Journal conducted by researchers at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) revealed risk factors for ...
Endocrinology Advisor11d
Diabetes Foot Screening Intervals Could Be Extended for Low-Risk Patients
Diabetic foot screening intervals could be extended beyond 1 year for patients at very low risk for diabetic foot complications.